Wired News – Portola Pharmaceuticals Provides Update On Commercial Launch of Bevyxxa(R)

Stock Monitor: Urogen Pharma Post Earnings
Reporting

LONDON, UK / ACCESSWIRE / November 27, 2017 / Active-Investors issued a free report on Portola
Pharmaceuticals, Inc. (NASDAQ: PTLA) (“Portola”), which is readily accessible upon registration
at www.active-investors.com/registration-sg/?symbol=PTLA as the Company’s latest news hit the wire. On November
21, 2017, the biopharmaceutical Company, which develops product candidates in
the fields of thrombosis and other hematologic diseases, announced that the US
Food and Drug Administration (“FDA”, or ‘the agency’) has extended the review
period for its Prior Approval Supplement (PAS) for Bevyxxa® (betrixaban). This
would give sufficient time to the agency to thoroughly review Portola’s
submission. Sign up now for our free
research reports at: www.active-investors.com/registration-sg.

Active-Investors.com is currently working on the research
report for Urogen Pharma Ltd (NASDAQ: URGN), which also belongs to the Healthcare
sector as the Company Portola Pharma. Do not miss out and become a member today
for free to access this upcoming report at: www.active-investors.com/registration-sg/?symbol=URGN.

Active-Investors.com is focused on
giving you timely information and the inside line on companies that matter to
you. This morning, Portola Pharma most recent news
is on our radar and we have decided to include it on our blog post. Today’s
free coverage is available at: www.active-investors.com/registration-sg/?symbol=PTLA.

About Bevyxxa®

Bevyxxa® is Portola’s first medicine. It
is an oral, once-daily Factor Xa inhibitor, which was approved by the FDA on
June 23, 2017.
Currently, Bevyxxa® is the first and only
anticoagulant for hospital and extended duration prophylaxis (i.e. around 35 to
42 days) of venous thromboembolism (VTE) in adult patients hospitalized for an
acute medical illness, and who are at risk for thromboembolic complications due
to moderate or severe restricted mobility and other risk factors for VTE.

Notification from the FDA

The FDA communicated to Portola that it
would revert on its PAS request to change the existing manufacturing release
specification within the standard extension period of 60 days.
The agency specified a new action date of
January 30, 2018.
However, the FDA did not ask for any
additional information from Portola at this point.

Bevyxxa® Commercial Launch Expected
in February 2018

Bill
Lis, Chief Executive Officer (CEO) at Portola, shared that the Company has made
good progress with the FDA for the product release so far. Portola has already
entered into an agreement in principle for the change of its product release
specification, which would help in the release and distribution of the existing
product inventory.

The
FDA might need more time to review the PAS application. And while the agency
completes its review, the momentum for Bevyxxa® within the medical community is
building. Portola expects to commercially launch Bevyxxa® by February 2018.
Till then, it intends to continue with its commercial and medical education
activities, in preparation for the launch.

Once
Bevyxxa® launches, it would prove to be a potentially life-saving new therapy
for VTE in hospitalized adult patients who at risk of developing VTE.

Portola Shared Third Quarter 2017
Results

Portola
reported its financial results on November 06, 2017, for the third quarter
ending September 30, 2017.

The total collaboration and license
revenue earned by the Company was $3.8 million, down from $9.3 million for the
third quarter of 2016.
Portola reported a net loss of $82.9
million, or $1.41 net loss per share, compared to a net loss of $92.9 million,
or $1.64 net loss per share, for the same period in 2016.
The net cash, cash equivalents, and
investments totaled $597.8 million.

Stock Performance Snapshot

November
24, 2017 – At Friday’s closing bell, Portola Pharma’s stock
fell 1.40%, ending the trading session at $50.55.

Volume traded for the
day: 330.61 thousand shares.

Stock performance in the
last month – up 3.50%; previous six-month period – up 37.66%; past twelve-month
period – up 167.04%; and year-to-date – up 125.27%

After last Friday’s
close, Portola Pharma’s market cap was at $3.35 billion.

The stock is part of the Healthcare
sector, categorized under the Biotechnology industry. This sector was up 0.3%
at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular
sponsored and non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ and Canadian
stocks. A-I has two distinct and independent departments. One department produces
non-sponsored analyst certified content generally in the form of press
releases, articles and reports covering equities listed on NYSE and NASDAQ and
the other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and micro-caps. Such
sponsored content is outside the scope of procedures detailed below.

A-I
has not been compensated; directly or indirectly; for producing or publishing
this document.

PRESS
RELEASE PROCEDURES:

The
non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service
company (the “Reviewer”) represented by a credentialed financial analyst [for
further information on analyst credentials, please email info@active-investors.com.
Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary
guidance in preparing the document templates. The Reviewer has reviewed and
revised the content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written and reviewed
on a reasonable-effort basis. The Reviewer has not performed any independent
investigations or forensic audits to validate the information herein. The
Reviewer has only independently reviewed the information provided by the Author
according to the procedures outlined by A-I. A-I is not entitled to veto or
interfere in the application of such procedures by the third-party research
service company to the articles, documents or reports, as the case may be.
Unless otherwise noted, any content outside of this document has no association
with the Author or the Reviewer in any way.

NO
WARRANTY

A-I,
the Author, and the Reviewer are not responsible for any error which may be
occasioned at the time of printing of this document or any error, mistake or
shortcoming. No liability is accepted whatsoever for any direct, indirect or
consequential loss arising from the use of this document. A-I, the Author, and
the Reviewer expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on the
information in this document. Additionally, A-I, the Author, and the Reviewer
do not (1) guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.

NOT
AN OFFERING

This
document is not intended as an offering, recommendation, or a solicitation of
an offer to buy or sell the securities mentioned or discussed, and is to be
used for informational purposes only. Please read all associated disclosures
and disclaimers in full before investing. Neither A-I nor any party affiliated
with us is a registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any
questions, inquiries, or comments reach out to us directly. If
you’re a company we are covering and wish to no longer feature on our coverage
list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from
Monday to Friday at:

Email: info@active-investors.com

Phone
number: 73 29 92 6381

Office
Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah
Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by
CFA Institute.

SOURCE: Active-Investors

ReleaseID: 482821